• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » An Unexpected Opioid: Loperamide Misuse

An Unexpected Opioid: Loperamide Misuse

May 21, 2021
Mara Storto, MD. and Deepti Anbarasan, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Mara Storto, MD. Psychiatric Resident, Psychiatry Residency Training Program, New York University Langone Health, New York, NY. Deepti Anbarasan, MD. Clinical Assistant Professor of Psychiatry, New York University, New York, NY. Dr. Storto and Dr. Anbarasan have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Loperamide, a common antidiarrheal available at pharmacies across the country, has unexpectedly become one of the latest in a growing trend of over-the-counter medications being repurposed for recreational use. Over the past 10 years, the broader public has discovered that supratherapeutic doses of loperamide can result in opioid-like euphoric effects. This information has been widely reported in internet forums that tout its use as a cheap “legal high.” Unfortunately, in addition to euphoria, large doses of loperamide have been associated with cardiotoxicity, respiratory depression, and even death.

Indication and mechanism
Commonly known by the brand name Imodium, loperamide can easily be purchased without a prescription. We prescribe or recommend it for patients with ostomies, GI distress related to opioid withdrawal, some forms of chronic diarrhea, or run-of-the-mill occasional diarrhea. Many clinicians don’t realize that loperamide is in fact a synthetic opioid. It slows down the gut by inhibiting intestinal peristalsis and allowing increased water absorption through its action as a mu-opioid receptor agonist in the intestinal tract, just like common opioids of abuse. Loperamide has historically been considered safe due to limited blood-brain permeability at its maximum recommended dose of 16 mg daily (Baker DE, Rev Gastroenterol Disord 2007;7:S11–S18). In other words, at therapeutic doses, loperamide does not act as an opioid agonist in the central nervous system, only in the gut, and therefore does not cause any of the analgesic or euphoric effects that we commonly associate with opioids.

Misuse
The significant GI distress that is experienced by patients in opioid withdrawal, characterized by diarrhea, nausea, and vomiting, can be treated appropriately with loperamide. Along with clonidine, ibuprofen, acetaminophen, and dicyclomine, loperamide is often a component of a symptom-based opioid detoxification protocol. In fact, it is thought that loperamide abuse first became widespread when patients taking it over the counter as a self-treatment for opioid withdrawal discovered that it could be taken regularly to keep withdrawal symptoms at bay. Given the inconvenience of daily methadone clinic visits, more and more posts on internet substance use message boards now recommend loperamide as a cheap and accessible alternative to methadone (Daniulaityte R et al, Drug Alcohol Depend 2013;130(1–3):241–244). Online users tout that supratherapeutic doses of loperamide (70–100 mg per day) result in central nervous system effects similar to methadone and can improve symptoms of opioid withdrawal. In fact, loperamide has recently come to be known as the “poor man’s methadone.”

Illicit drug websites discuss the use of “lope” at single doses of up to 400 mg to achieve an opioid high (the maximum recommended single dose is 4 mg). Once doses get above 25 times the recommended maximum daily dose, loperamide does cross the blood-brain barrier to achieve central nervous system effects, such as euphoria and analgesia. To further enhance these effects, users take loperamide in combination with P450 inhibitors that slow its metabolism and excretion, like quinine, quinidine, and cimetidine.

Studies looking at the number of calls to poison centers reporting loperamide overdoses, as well as analyses of Google search trends, have revealed the growing concern of loperamide’s abuse potential (Borron SW et al, J Emerg Med 2017;53(1):73–84). From 2010 to 2015, there was a 91% increase in intentional loperamide exposures reported to the National Poison Data System—a worrying trend given the potentially lethal effects of loperamide taken at such high doses (Vakkalanka JP et al, Ann Emerg Med 2017;69(1):73–78). Loperamide manufacturers have gotten wary and capped the dose of a single pill at 2 mg. Packages typically contain loperamide exclusively in blister packs, and some pharmacies limit the number of packages that an individual can buy.

Side effects and toxicity
At recommended doses, the side effects of loperamide are mild and the medication is generally acknowledged to be safe. However, at the high supratherapeutic doses taken to achieve euphoria, frank opioid intoxication occurs with characteristic respiratory depression, pinpoint pupils, and sedation. Furthermore, like methadone, high-dose loperamide interferes with cardiac conduction and can cause dangerous arrhythmias. Many case studies have detailed QRS widening and QT prolongation, resulting in an increased risk of torsades de pointes (Marraffa JM et al, Clin Toxicol (Phila) 2014;52(9):952–957; Katz KD et al, J Emerg Med 2017;53(3):339–344).

Why is this important?
There is clear evidence of the rising popularity of loperamide abuse. As a result, in 2016 the FDA released a warning that high doses of loperamide can cause abnormal heart rhythms and serious cardiac events. Loperamide is not tested on the standard urine drug screen, so it is important for us to recognize and consider loperamide toxicity. In the case of acute toxicity, naloxone can be given for respiratory depression. Given the high risk of arrhythmias, these patients should be transferred to an inpatient unit with telemetry and receive a cardiology consultation (Eggleston W et al, Clin Toxicol (Phila) 2020;58(5):355–359). Unfortunately, we don’t have any research about how best to treat patients with loperamide use disorder. It is unclear whether these patients require detoxification or whether buprenorphine, methadone, or naltrexone are helpful.

CATR Verdict: Remain wary of loperamide abuse, particularly in patients with signs of opioid toxicity but a negative urine drug screen. Patients intoxicated on loperamide need inpatient admission and a cardiology consultation.
Addiction Treatment
KEYWORDS free_articles opioids over-the-counter-medication safety side-effects
    Mara Storto, MD.

    More from this author
    Deepti Anbarasan, MD.

    Can Assertive Treatment Improve Treatment Adherence in Young Adults With Opioid Use Disorder?

    More from this author
    www.thecarlatreport.com
    Issue Date: May 21, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Welcoming Our New Editor-in-Chief
    Pharmacotherapy for Stimulant Use Disorders
    Diagnosing and Treating Stimulant Use Disorders
    An Unexpected Opioid: Loperamide Misuse
    A Psychosocial Intervention for Chronic Pain and SUD
    CME Post-Test - Stimulant Use Disorder, CATR, May/June 2021
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.